131 related articles for article (PubMed ID: 22349110)
1. Risk of breast cancer in patients on long-acting insulin analogues in comparison with those on human insulin.
Kostev K
Diabetologia; 2012 May; 55(5):1554-5. PubMed ID: 22349110
[No Abstract] [Full Text] [Related]
2. Request for clarification from Ruiter et al regarding 'Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study'.
Carstensen B
Diabetologia; 2012 Mar; 55(3):857-8; author reply 859-60. PubMed ID: 22222505
[No Abstract] [Full Text] [Related]
3. Insulin analogues and cancer risk: the emergence of second-generation studies.
Renehan AG
Diabetologia; 2012 Jan; 55(1):7-9. PubMed ID: 22033621
[TBL] [Abstract][Full Text] [Related]
4. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
Diabetologia; 2012 Jan; 55(1):51-62. PubMed ID: 21956710
[TBL] [Abstract][Full Text] [Related]
5. [Increased risk of cancer using insulin and insulin analogues?].
Schäffler A
MMW Fortschr Med; 2010 Sep; 152(36):39-41. PubMed ID: 21192466
[No Abstract] [Full Text] [Related]
6. Insulin detemir (levemir), a new long-acting insulin.
Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
[TBL] [Abstract][Full Text] [Related]
7. [Clinical use of long-acting insulin analogs].
Birkeland KI
Tidsskr Nor Laegeforen; 2006 Apr; 126(8):1067-8. PubMed ID: 16619068
[No Abstract] [Full Text] [Related]
8. Effects of insulin detemir and NPH insulin on renal handling of sodium, fluid retention and weight in type 2 diabetic patients.
Hendriksen KV; Jensen T; Oturai P; Feldt-Rasmussen B
Diabetologia; 2012 Jan; 55(1):46-50. PubMed ID: 22002075
[TBL] [Abstract][Full Text] [Related]
9. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.
Frier BM; Russell-Jones D; Heise T
Diabetes Obes Metab; 2013 Nov; 15(11):978-86. PubMed ID: 23551900
[TBL] [Abstract][Full Text] [Related]
10. Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
Owens DR; Matfin G; Monnier L
Diabetes Metab Res Rev; 2014 Feb; 30(2):104-19. PubMed ID: 24026961
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety of long-acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
Chang CH; Chuang LM
J Diabetes Investig; 2018 Jul; 9(4):728-730. PubMed ID: 29140602
[No Abstract] [Full Text] [Related]
12. [Urticaria after subcutaneous administration of Insulatard].
Hruz P; Stöckli R; Bircher A
Praxis (Bern 1994); 2007 May; 96(19):781-2. PubMed ID: 17571635
[No Abstract] [Full Text] [Related]
13. Hypersensitivity reaction to a biosimilar insulin glargine.
García-Nares H; Leyva-Carmona MI; Pérez-Xochipa N; Chiquete E
J Diabetes; 2015 Mar; 7(2):155-7. PubMed ID: 25350350
[No Abstract] [Full Text] [Related]
14. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.
Rosenstock J; Fonseca V; McGill JB; Riddle M; Hallé JP; Hramiak I; Johnston P; Davis M
Diabetologia; 2009 Sep; 52(9):1971-3. PubMed ID: 19609501
[No Abstract] [Full Text] [Related]
15. Insulin degludec. Uncertainty over cardiovascular harms.
Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
[TBL] [Abstract][Full Text] [Related]
16. Insulin degludec for diabetes mellitus.
Drug Ther Bull; 2013 Jul; 51(7):78-81. PubMed ID: 23842634
[TBL] [Abstract][Full Text] [Related]
17. [Insulin glargine and cancer: a storm in a glass of water?].
Scheen AJ; Lefebvre PJ
Rev Med Liege; 2009 Sep; 64(9):440-5. PubMed ID: 19947313
[TBL] [Abstract][Full Text] [Related]
18. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
Hemkens LG; Grouven U; Bender R; Günster C; Gutschmidt S; Selke GW; Sawicki PT
Diabetologia; 2009 Sep; 52(9):1732-44. PubMed ID: 19565214
[TBL] [Abstract][Full Text] [Related]
19. Macro- and microvascular outcomes in patients with type 2 diabetes treated with rapid-acting insulin analogues or human regular insulin: a retrospective database analysis.
Rathmann W; Schloot NC; Kostev K; Reaney M; Zagar AJ; Haupt A
Exp Clin Endocrinol Diabetes; 2014 Feb; 122(2):92-9. PubMed ID: 24558019
[TBL] [Abstract][Full Text] [Related]
20. Insulin analogues and severe hypoglycaemia in type 1 diabetes.
Kristensen PL; Hansen LS; Jespersen MJ; Pedersen-Bjergaard U; Beck-Nielsen H; Christiansen JS; Nørgaard K; Perrild H; Parving HH; Thorsteinsson B; Tarnow L
Diabetes Res Clin Pract; 2012 Apr; 96(1):17-23. PubMed ID: 22136722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
